Granules India rose 1.07% to Rs 619 after its arm Granules Pharmaceuticals, Inc has received tentative approval from the USFDA for its Abbreviated New Drug Application for generic Amphetamine Extended ...

The FDA has permitted for marketing the first medical device indicated for the treatment of attention deficit hyperactivity disorder ADHD. The Food and Drug Administration (FDA) has permitted for ...

A Prescription Drug User Fee Act target date of May 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

For decades, ADHD stimulant medications have been thought to sharpen attention, but new research has uncovered something very ...

Active ingredient: Guanfacine (as HCl) 1 mg, 2 mg, 3 mg, 4 mg; extended-release tabs. Indication: Attention- deficit hyperactivity disorder (ADHD) in patients aged 6-17 years. Clinical trials: The ...

Arynta is a medicine used to treat attention deficit hyperactivity disorder (ADHD). ADHD is a common condition in children, and it also affects adults. ADHD affects how you pay attention, focus, and ...

London: The increase in attention-deficit hyperactivity disorder (ADHD) diagnoses across the seven major markets (7MM*) is attributed to the adoption of updated clinical guidelines and standardized ...